Gastroparesis Treatment Pipeline Shows Strong Momentum as 6+ Pharma Companies in the Race | DelveInsight

DelveInsight's, "Gastroparesis Pipeline Insight, 2025" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Gastroparesis pipeline landscape. It covers the Gastroparesis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastroparesis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Gastroparesis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Gastroparesis Pipeline Report
• On Dec. 4, 2025- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for tradipitant, intended for the treatment of gastroparesis symptoms.
• In October 2025, CinDome Pharma Inc. announced a clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
• DelveInsight's Gastroparesis pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Gastroparesis treatment.
• The leading Gastroparesis Companies such as CinDome Pharma Inc., Aclipse Therapeutics, and others.
• Promising Gastroparesis Pipeline Therapies such as Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, VLY-686 (Tradipitant), GM-611 and others.

Discover how the Gastroparesis Treatment paradigm is evolving. Access DelveInsight's in-depth Gastroparesis Pipeline Analysis for a closer look at promising breakthroughs @ https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Gastroparesis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Gastroparesis Pipeline Report also highlights the unmet needs with respect to the Gastroparesis.

Gastroparesis Overview
Gastroparesis is a condition characterized by delayed gastric emptying without any mechanical obstruction, leading to symptoms like nausea, vomiting, bloating, early fullness, and abdominal pain. This disorder results from abnormal motor function in the stomach, involving complex interactions between the nervous system, stomach muscles, and other gastrointestinal components. While the exact cause is often unknown (idiopathic), it can also be linked to diabetes, surgery, or infections. As its incidence rises, particularly due to increased rates of diabetes and obesity, gastroparesis is often confused with functional dyspepsia. Effective treatment is challenging and generally involves managing symptoms through medication, dietary changes, and lifestyle adjustments.

Gastroparesis Emerging Drugs Profile
• CIN-102: CinDome Pharma, Inc.
Deudomperidone (CIN-102) is a novel chemical entity derived through deuteration and reformulation of domperidone, a widely prescribed first-line therapy for nausea, vomiting, and gastroparesis. Orally administered, it has been specifically designed to modify the pharmacokinetic profile, delivering sustained efficacy while markedly reducing cardiac risk. Clinical trials have consistently shown deudomperidone to be well tolerated, with no sponsor-assessed drug-related adverse events or clinically significant laboratory abnormalities observed. Currently, the drug is in Phase II stage of its development for the treatment of Gastroparesis.

The Gastroparesis Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Gastroparesis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroparesis Treatment.
• Gastroparesis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastroparesis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroparesis market

Explore groundbreaking therapies and clinical trials in the Gastroparesis Pipeline. Access DelveInsight's detailed report now! @ https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroparesis Companies
CinDome Pharma Inc., Aclipse Therapeutics, and others.

Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Gastroparesis Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Gastroparesis Pipeline Report
• Coverage- Global
• Gastroparesis Companies- CinDome Pharma Inc., Aclipse Therapeutics, and others.
• Gastroparesis Pipeline Therapies- Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, VLY-686 (Tradipitant), GM-611 and others.
• Gastroparesis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastroparesis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Gastroparesis drug development? Find out in DelveInsight's exclusive Gastroparesis Pipeline Report-access it now! @ https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Gastroparesis : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Gastroparesis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. CIN-102: CinDome Pharma, Inc.
10. Early Stage Products (Phase I)
11. Preclinical and Discovery Stage Products
12. Inactive Products
13. Gastroparesis Key Companies
14. Gastroparesis Key Products
15. Gastroparesis - Unmet Needs
16. Gastroparesis - Market Drivers and Barriers
17. Gastroparesis - Future Perspectives and Conclusion
18. Gastroparesis Analyst Views
19. Gastroparesis Key Companies
20. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.